Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 20, 2021 10:16pm
264 Views
Post# 34150112

RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics Additionally. chimeric antigen receptor (CAR)-T cell therapy, a type of adoptive cell therapy that combines the antigen specificity of an antibody with the effector functions of a T cell, has emerged as a promising immunotherapeutic strategy to improve the survival rates of patients with TNBC. Unlike the remarkable clinical success of CAR-T cell therapies in hematologic cancers with Kymriah and Yescarta, the development of CAR-T cell therapies for solid tumors has been much slower and is associated with unique challenges, including a hostile tumor microenvironment (TME).

ONCY's oncolytic virus pelareorep has demonstrated that can overcome a hostile TME while also demonstrating a synergistic effect when combined with CAR-T therapy, as evidenced by the work of Dr. Richard Vile of the Mayo Clinic.

Furthermore, ONCY's pelareorep is able to be synergistically combined with immune checkpoint inhibitors and CAR-T therapy, which in turn could be subsequenty combined with antibody drug conjugates (ADC), PARP & CDK 4,6 inhibitors, and bispecifics for effective treatment of liquid and solid tumors.

Consequently, ONCY is demonstrating that pelareorep is able to be combined with multiple IO agents, adoptive cell therapies, and small molecules to potentially treat various multiple cancers with current unmet treatment needs.
<< Previous
Bullboard Posts
Next >>